Residual adrenal function in autoimmune Addison's disease: improvement after tetracosactide (ACTH1-24) treatment

J Clin Endocrinol Metab. 2014 Jan;99(1):111-8. doi: 10.1210/jc.2013-2449. Epub 2013 Dec 20.


Context: Despite lifelong steroid hormone replacement, there is excess morbidity and mortality associated with autoimmune Addison's disease. In health, adrenocortical cells undergo continuous self-renewal from a population of subcapsular progenitor cells, under the influence of ACTH, suggesting a therapeutic possibility.

Objective: We aimed to determine whether tetracosactide (synthetic ACTH1-24) could revive adrenal steroidogenic function in autoimmune Addison's disease.

Design, setting, and patients: Thirteen patients (aged 16-65 y) with established autoimmune Addison's disease for more than 1 year were recruited at the Newcastle University Clinical Research Facility.

Intervention: The intervention included a 20-week study of regular sc tetracosactide (ACTH1-24) therapy.

Main outcome measures: Serum and urine corticosteroids were measured during medication withdrawal at baseline and every 5 weeks during the study.

Results: Serum cortisol levels remained less than 100 nmol/L in 11 of 13 participants throughout the study. However, two women achieved peak serum cortisol concentrations greater than 400 nmol/L after 10 and 29 weeks of tetracosactide therapy, respectively, allowing withdrawal of corticosteroid replacement. Concurrently, urine glucocorticoid and mineralocorticoid metabolite excretion increased from subnormal to above the median of healthy controls. One of these responders remains well with improving peak serum cortisol (672 nmol/L) 28 months after stopping all treatments. The other responder showed a gradual reduction in serum cortisol and aldosterone over time, and steroid therapy was recommenced after a 28-week period without glucocorticoid replacement.

Conclusion: This is the first study to demonstrate that established autoimmune Addison's disease is amenable to a regenerative medicine therapy approach.

Trial registration: NCT01371526.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Addison Disease / drug therapy*
  • Addison Disease / metabolism
  • Addison Disease / physiopathology*
  • Adolescent
  • Adrenal Cortex Hormones / blood
  • Adrenal Cortex Hormones / urine
  • Adrenal Glands / drug effects*
  • Adrenal Glands / physiology*
  • Adult
  • Aged
  • Cosyntropin / therapeutic use*
  • Female
  • Humans
  • Infusion Pumps
  • Male
  • Middle Aged
  • Remission Induction
  • Treatment Outcome
  • Young Adult


  • Adrenal Cortex Hormones
  • Cosyntropin
  • adrenocorticotropin zinc

Associated data